Halozyme Therapeutics, Inc.
$68.8
▲
0.57%
2026-04-22 10:12:13
halozyme.com
NMS: HALO
Explore Halozyme Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.18 B
Current Price
$68.8
52W High / Low
$82.22 / $47.5
Stock P/E
26.89
Book Value
$0.41
Dividend Yield
—
ROCE
34.18%
ROE
1.54%
Face Value
—
EPS
$2.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
423
Beta
1.03
Debt / Equity
4,460.19
Current Ratio
4.66
Quick Ratio
3.66
Forward P/E
6.92
Price / Sales
5.75
Enterprise Value
$10.04 B
EV / EBITDA
11.18
EV / Revenue
7.19
Rating
Buy
Target Price
$84.89
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Leverage is relatively high.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Oncolytics Biotech Inc. | $1.11 | — | $163.05 M | — | -1939.57% | 11480.64% | $1.85 / $0.45 | $0 |
| 2. | Kymera Therapeutics, Inc. | $88.84 | — | $7.31 B | — | -20.82% | -25.78% | $103 / $24.43 | $19.42 |
| 3. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 4. | Jaguar Health, Inc. | $0.41 | — | $5.34 M | — | -91.43% | -628.65% | $15.48 / $0.31 | $0.85 |
| 5. | Enanta Pharmaceuticals, Inc. | $13.78 | — | $409.17 M | — | -36.76% | -60.01% | $17.15 / $4.83 | $4.36 |
| 6. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 7. | TransCode Therapeutics, Inc. | $8.88 | — | $8.07 M | — | -334.68% | -17.63% | $22.03 / $6.08 | $1.71 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 451.77 M | 354.26 M | 325.72 M | 264.86 M | 298.01 M | — |
| Operating Profit | 240.7 M | 217.92 M | 202.44 M | 141.53 M | 175.5 M | — |
| Net Profit | -141.59 M | 175.22 M | 165.16 M | 118.09 M | 137.01 M | — |
| EPS in Rs | -1.2 | 1.48 | 1.39 | 1 | 1.16 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.4 B | 1.02 B | 829.25 M | 660.12 M |
| Operating Profit | 802.59 M | 551.48 M | 337.57 M | 267.53 M |
| Net Profit | 316.89 M | 444.09 M | 281.59 M | 202.13 M |
| EPS in Rs | 2.67 | 3.75 | 2.38 | 1.71 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.53 B | 2.06 B | 1.73 B | 1.84 B |
| Total Liabilities | 2.48 B | 1.7 B | 1.65 B | 1.67 B |
| Equity | 48.81 M | 363.82 M | 83.81 M | 169.8 M |
| Current Assets | 825.21 M | 1.09 B | 746.42 M | 739.01 M |
| Current Liabilities | 177.09 M | 139.1 M | 112.49 M | 130.79 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 651.56 M | 479.06 M | 388.57 M | 240.11 M |
| Investing CF | -545.81 M | -262.72 M | -96.91 M | -487 M |
| Financing CF | -85.17 M | -218.86 M | -407.99 M | 362.37 M |
| Free CF | 356.82 M | 468.37 M | 373.28 M | 235.3 M |
| Capex | -294.74 M | -10.7 M | -15.29 M | -4.81 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 22.44% | 25.62% | — | — |
| Earnings Growth % | 57.71% | 39.31% | — | — |
| Profit Margin % | 43.74% | 33.96% | 30.62% | — |
| Operating Margin % | 54.32% | 40.71% | 40.53% | — |
| Gross Margin % | 84.3% | 76.8% | 78.9% | — |
| EBITDA Margin % | 64.66% | 54.5% | 47.8% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.